Table 1.
Clinical characteristics of patients with NMOSD
| Patient number | Age at sampling | Sex | Ethnicity | Disease localization | Time since first event (days) | Time since last relapse (days) | Duration of IT (days) | Current IT (daily dose) | Serum AQP4-IgG level (ΔMFI) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 41 | F | Caucasian | TM | 1741 | 664 | 1199 | Pred 15 mg | 26 610 |
| 2 | 67 | F | Caucasian | TM | 1224 | 1141 | 1218 | AZA 125 mg | 15 267 |
| 3 | 36 | F | Asian | ON and TM | 7653 | 72 | 1442 | Pred 20 mg; MMF 3 g | 6126 |
| 4 | 50 | F | African | TM | 433 | 433 | 413 | Pred 25 mg; MMF 1.5 g | 3080 |
| 5 | 44 | M | Caucasian | TM | 2364 | 93 | 2344 | Pred 10 mg; MMF 2.5 g | 1863 |
| 6 | 55 | F | Caucasian | ON | 1728 | 1671 | 1708 | MMF 2.5 g | 1742 |
| 7 | 67 | F | Caucasian | TM | 3411 | 1798 | 1788 | Pred 10 mg; MMF 2 g | 1350 |
| 8 | 75 | F | Caucasian | TM | 688 | 688 | 668 | Pred 10 mg; MMF 2 g | 422 |
| 9 | 52 | F | Caribbean | ON and TM | 1125 | 667 | 1120 | Pred 15 mg; MMF 2 g | 209 |
| 10 | 18 | F | African | Brain, TM | 12 | 12 | 12 | Pred 40 mg | 91 |
| 11 | 57 | F | Caucasian | TM | 8589 | 2958 | 3108 | RTX | 402 |
| 12 | 37 | F | Caribbean | Brain, ON and TM | 3609 | 47 | 3243 | Pred 20 mg; RTX | 235 |
Serum AQP4-IgG levels determined by flow cytometry as described in Fig. 3 (ΔMFI, as defined in Methods). AZA = azathioprine; IT = immunotherapy; MMF = mycophenolate mofetil; ON = optic neuritis; Pred = prednisolone; TM = transverse myelitis; RTX = rituximab. Only Patients 11 and 12 ever received rituximab. Lymphocyte subsets are presented in Supplementary Table 1.